Institute Research Scientist, MD Anderson Cancer Center
Therapeutic targeting of metabolic synthetic lethality in cancer research
Presented at:
Immuno-Oncology & Cancer Biology Virtual Conference
Speaker
Abstract
In this webinar, Dr. Yuting Sun discusses her research supporting a Phase 1 clinical trial advancing cancer therapies, targeted at metabolic vulnerabilities. Metabolic rewiring is a hallmark of cancer. However, the plasticity of preexisting regulatory circuit compromises the effectiveness of targeted therapies. We postulate that leveraging genetic vulnerabilities in cancer cells may overcome such adaptations. In this presentation, we discuss strategies in targeting two distinct metabolic vulnerabilities- FHmut cancer and glycolysis-deficient cancer.
Learning Objectives:
1. Targeting redox balance in FHmut cancer
2. Targeting OXPHOS in glycolysis deficient tumor
3. Utilization of seahorse assay supporting Phase 1 clinical trial (for research use)
You May Also Like
DEC 10, 2024 | 9:00 AM
To-date, proteomic analysis has been severely limited in scale and resolution. Analyzing protein samples using an intact, single-molecule approach holds th...
MAY 29, 2024 | 8:00 AM
A-TEEM spectroscopy is an emerging technique with huge potential for QC laboratories in the pharmaceutical and biopharmaceutical industries. We present a set of tools for A-TEEM spectroscopy...
MAY 29, 2024 | 9:00 AM
C.E. CREDITS
Histology laboratorians in the research world move fast, but those who perform cryosectioning know that these particular tissues require lighting speed and precision. Cryosectioning is the a...
JUN 19, 2024 | 8:30 AM
Join us for an illuminating webinar as we delve into the realm of open automation with Inpeco, the global leader in Total Laboratory Automation. Discover how their groundbreaking s...
Loading Comments...